This review is a summary of evidence in support of benralizumab use as add-on maintenance treatment for severe refractory asthma in patients with an eosinophilic endotype.
The review focuses on the pathophysiology, epidemiology and management of severe refractory asthma,
and on the pharmacological, clinical, and safety profiles of benralizumab.
Independent commentary has been provided by Philip Thompson, Director of the Lung Health
Clinic, Hollywood Hospital, the Complex Airways Clinic, Sir Charles Gairdner Hospital,
and Clinical Professor at the Universities of Western Australia and Curtin.
Please login below to download this issue (PDF)